(University of Washington) Determining TB treatment based on a patient's sequence at gene called LTA4H could improve outcomes.
This gene controls the balance between pro-inflammatory and anti-inflammatory substances produced during an infection.
Mutations leading to a tilt in either direction increases TB severity. Drugs helpful for a hot responder could be ineffective for cool responders.